Stockscreener 앱 받기
14.09
6.75%
-1.02
시간 외 거래:
14.09
전일 마감가:
$15.11
열려 있는:
$14.91
하루 거래량:
375.31K
Relative Volume:
0.56
시가총액:
$849.28M
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-3.4181
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
-3.95%
1개월 성능:
+10.16%
6개월 성능:
-60.77%
1년 성능:
-60.62%
1일 변동 폭
$13.93
$15.10
1주일 범위
$13.93
$15.77
52주 변동 폭
$10.91
$40.49
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
14.09 | 849.28M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World
Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq
Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus
Clinical Trial Shows 3X Longer Half-Life for Spyre IBD Drug vs Standard Treatment | SYRE Stock News - Stock Titan
Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan
Spyre Therapeutics (SYRE) to Release Earnings on Thursday - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Barclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Analyzing Ratios: Arcutis Biotherapeutics Inc (ARQT)’s Financial Story Unveiled - DWinneX
JPMorgan Chase & Co. Purchases 5,775 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Inc [SYRE] stock for 246,313 USD was sold by Albers Jeffrey W. - knoxdaily.com
Are Smart Investors Making the Right Decision? Spyre Therapeutics Inc (SYRE) - Sete News
Have you been able to find a good deal on Spyre Therapeutics Inc’s shares? - uspostnews.com
Analyzing the Impact of Earnings Reports on Spyre Therapeutics Inc Inc. (SYRE) Price Performance - investchronicle.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Geode Capital Management LLC - The AM Reporter
What is Leerink Partnrs’ Forecast for SYRE Q1 Earnings? - The AM Reporter
Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Q1 Earnings Estimate for SYRE Issued By Leerink Partnrs - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Consensus Price Target from Brokerages - Defense World
Corebridge Financial Inc. Has $401,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Leerink Partnrs Upgrades Spyre Therapeutics (NASDAQ:SYRE) to “Strong-Buy” - Defense World
KLP Kapitalforvaltning AS Invests $182,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target - marketscreener.com
Biotech Spyre Therapeutics Awards 93,200 Stock Options in Key Talent Push - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week LowHere's Why - MarketBeat
Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – What’s Next? - Defense World
Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Natixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PR Newswire
Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World
Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Will Spyre Therapeutics Redefine IBD Treatment With Superior Efficacy And Convenience? - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World
Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com
Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News
Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):